GGrantIndex
← Leaderboards

Jennifer R Brown

Dana-Farber Cancer Institute

$9,365,864
Attributed
$10,260,669
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,260,669 · 5

By mechanism

R01$6,055,392 · 2
T32$1,789,610 · 1
P01$1,662,114 · 1
K23$753,553 · 1

Top collaborators

Most similar at Dana-Farber Cancer Institute

Same institution · by research overlap

Others in their field

Top investigators on “Genetic

Research focus

GeneticDana-Farber Cancer InstituteTissue BanksEnrollmentClinical TrialsMalignant NeoplasmsGrantResourcesBiologyClinicInvestigationCellsProspectiveBaseFirst Degree RelativeGenetic Linkage AnalysisFamilyGenetic Predisposition To DiseaseGenomeCell LineBiologicalHigh RiskCohortCandidate Disease Gene

Grant awards (25)

Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)$591,132
R01 · FY2025 · CA · contact PI
Physician Scientist Training in Cancer Research$450,297
T32 · FY2025 · CA
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)$561,576
R01 · FY2024 · CA · contact PI
Physician Scientist Training in Cancer Research$444,800
T32 · FY2024 · CA
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)$668,037
R01 · FY2023 · CA · contact PI
Physician Scientist Training in Cancer Research$538,994
T32 · FY2023 · CA
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)$644,443
R01 · FY2022 · CA · contact PI
Physician Scientist Training in Cancer Research$355,519
T32 · FY2022 · CA
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)$678,292
R01 · FY2021 · CA · contact PI
Unlocking the Potential of PI3K Inhibition in CLL$571,051
R01 · FY2021 · CA · contact PI
Unlocking the Potential of PI3K Inhibition in CLL$571,051
R01 · FY2020 · CA · contact PI
Biospecimens and Primagraft Development$316,409
P01 · FY2020 · CA · contact PI
Unlocking the Potential of PI3K Inhibition in CLL$578,547
R01 · FY2019 · CA · contact PI
Biospecimens and Primagraft Development$309,508
P01 · FY2019 · CA · contact PI
Unlocking the Potential of PI3K Inhibition in CLL$596,117
R01 · FY2018 · CA · contact PI
Biospecimens and Primagraft Development$326,180
P01 · FY2018 · CA · contact PI
Unlocking the Potential of PI3K Inhibition in CLL$595,146
R01 · FY2017 · CA · contact PI
Biospecimens and Primagraft Development$326,180
P01 · FY2017 · CA · contact PI
Biospecimens and Primagraft Development$383,837
P01 · FY2016 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$136,890
K23 · FY2009 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$69,120
K23 · FY2009 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$136,890
K23 · FY2008 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$136,890
K23 · FY2007 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$136,890
K23 · FY2006 · CA · contact PI
Genetic Alterations in Families with Multiple Lymphomas$136,873
K23 · FY2005 · CA